Literature DB >> 16878308

Quantitative dynamic contrast-enhanced MRI in tumor-bearing rats and mice with inversion recovery TrueFISP and two contrast agents at 4.7 T.

Claudia Weidensteiner1, Martin Rausch, Paul M J McSheehy, Peter R Allegrini.   

Abstract

PURPOSE: To characterize tumor vascularization by dynamic-contrast enhanced (DCE) MRI using low and medium molecular weight paramagnetic contrast agents (CA) and inversion recovery (IR) true fast imaging with steady state precession (TrueFISP) in tumor-bearing rats and mice.
MATERIALS AND METHODS: T(1) mapping was performed using IR True FISP in phantoms and in vivo at 4.7 T and validated with a segmented IR gradient-echo (IR GE) method. CA concentration in DCE-MRI studies in vivo was calculated from time-series T(1) maps using the CAs GdDOTA and P792 (low and medium molecular weight, respectively). Standard vascular input functions (VIFs) were measured in the jugular veins and were used for modeling of the CA kinetics with a two-compartment model. In rat breast tumors, vascular permeability (transfer constant K(trans)), fractional plasma volume v(p), and fractional leakage space v(e) were quantified and parametric maps were generated.
RESULTS: The IR TrueFISP T(1) was slightly underestimated in phantoms and overestimated in vivo (10%) with respect to IR GE. VIFs showed only small interindividual variation. Mean K(trans) values were 0.062 +/- 0.017 min(-1) for GdDOTA and 0.015 +/- 0.005 min(-1) for P792 (N = 12). Mean v(e) and v(p) values were 0.15 +/- 0.04 (0.09 +/- 0.03) and 0.04 +/- 0.01 (0.03 +/- 0.01) for GdDOTA (P792).
CONCLUSION: DCE-MRI with IR TrueFISP provided absolute values for K(trans), v(p), and v(e). Direct comparison between GdDOTA and P792 revealed significant differences in the VIF, model-fit-quality, permeability, leakage space, and plasma volume. The larger molecular weight CA P792 appears to be better for measuring tumor vascular parameters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16878308     DOI: 10.1002/jmri.20676

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  10 in total

1.  Distinct patterns of kidney and liver cyst growth in pkd2(WS25/-) mice.

Authors:  R Brian Doctor; Natalie J Serkova; Kendra M Hasebroock; Iram Zafar; Charles L Edelstein
Journal:  Nephrol Dial Transplant       Date:  2010-04-13       Impact factor: 5.992

2.  Use of a reference tissue and blood vessel to measure the arterial input function in DCEMRI.

Authors:  Xiaobing Fan; Chad R Haney; Devkumar Mustafi; Cheng Yang; Marta Zamora; Erica J Markiewicz; Gregory S Karczmar
Journal:  Magn Reson Med       Date:  2010-12       Impact factor: 4.668

3.  High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI.

Authors:  M M Pike; C N Stoops; C P Langford; N S Akella; L B Nabors; G Y Gillespie
Journal:  Magn Reson Med       Date:  2009-03       Impact factor: 4.668

4.  A dedicated automated injection system for dynamic contrast-enhanced MRI experiments in mice.

Authors:  Jan Sedlacik; Adrianne Myers; Ralf B Loeffler; Regan F Williams; Andrew M Davidoff; Claudia M Hillenbrand
Journal:  J Magn Reson Imaging       Date:  2012-09-21       Impact factor: 4.813

5.  Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model.

Authors:  Sanaz A Jansen; Tatjana Paunesku; Xiaobing Fan; Gayle E Woloschak; Stefan Vogt; Suzanne D Conzen; Thomas Krausz; Gillian M Newstead; Gregory S Karczmar
Journal:  Radiology       Date:  2009-11       Impact factor: 11.105

6.  Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation.

Authors:  Tista Roy Chaudhuri; Robert D Arnold; Jun Yang; Steven G Turowski; Yang Qu; Joseph A Spernyak; Richard Mazurchuk; Donald E Mager; Robert M Straubinger
Journal:  Pharm Res       Date:  2012-07-14       Impact factor: 4.200

7.  Preclinical models for neuroblastoma: establishing a baseline for treatment.

Authors:  Tal Teitz; Jennifer J Stanke; Sara Federico; Cori L Bradley; Rachel Brennan; Jiakun Zhang; Melissa D Johnson; Jan Sedlacik; Madoka Inoue; Ziwei M Zhang; Sharon Frase; Jerold E Rehg; Claudia M Hillenbrand; David Finkelstein; Christopher Calabrese; Michael A Dyer; Jill M Lahti
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

8.  Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies.

Authors:  Sander M Bison; Joost C Haeck; K Bol; S J Koelewijn; H C Groen; M Melis; J F Veenland; M R Bernsen; M de Jong
Journal:  EJNMMI Res       Date:  2015-11-09       Impact factor: 3.138

9.  DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data.

Authors:  Juan E Ortuño; María J Ledesma-Carbayo; Rui V Simões; Ana P Candiota; Carles Arús; Andrés Santos
Journal:  BMC Bioinformatics       Date:  2013-11-04       Impact factor: 3.169

10.  Imaging heterogeneity of peptide delivery and binding in solid tumors using SPECT imaging and MRI.

Authors:  J C Haeck; K Bol; C M A de Ridder; L Brunel; J A Fehrentz; J Martinez; W M van Weerden; M R Bernsen; M de Jong; J F Veenland
Journal:  EJNMMI Res       Date:  2016-01-14       Impact factor: 3.138

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.